|1st December 2020||Dan Puckett||200||Open or private sale||$95.41||$19,082.00|
|1st December 2020||Dan Puckett||900||Open or private sale||$94.59||$85,131.00|
|1st December 2020||Dan Puckett||200||Open or private sale||$96.43||$19,286.00|
|1st December 2020||Dan Puckett||700||Open or private sale||$93.17||$65,219.00|
|1st December 2020||Dan Puckett||1,659||Exercise of derivative||$17.00||$28,203.00|
|1st December 2020||Dan Puckett||341||Exercise of derivative||$3.42||$1,164.86|
|23rd November 2020||Antoine Papiernik||16,955||Open or private sale||$101.00||$1,712,455.00|
|23rd November 2020||Antoine Papiernik||28,500||Open or private sale||$99.02||$2,822,070.00|
|20th November 2020||Antoine Papiernik||1,500||Open or private sale||$99.03||$148,545.00|
|20th November 2020||Antoine Papiernik||21,900||Open or private sale||$97.03||$2,124,957.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Shockwave Medical, Inc. operates as a medical device company. It focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The firm offers M5 catheters for treating above-the-knee peripheral artery disease.